Androgen therapy in myelodysplastic syndromes with thrombocytopenia: a report on 20 cases

Eric Wattel, E Wattel, Nathalie Cambier, N Cambier, M T Caulier, Marie‐Thérèse Caulier, Daniele Sautiere, D Sautière, F Bauters, P Fenaux, Pierre Fenaux
British journal of haematology · 1994 · vol. 87(1) , pp. 205–208 · doi:10.1111/j.1365-2141.1994.tb04895.x · PMID:7947249 · W1967615994
Non-randomised trial OA: closed CC0 ⤵ 10 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-09 ⓘ

Androgen therapy in 20 myelodysplastic syndrome patients with severe thrombocytopenia increased platelet counts by at least 30 x 10(9)/l in 55% and resolved bleeding symptoms in all patients with initial bleeding.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Twenty patients with myelodysplastic syndromes (MDS) and (i) platelets < 50 x 10(9)/l and (ii) bone marrow blasts < or = 10% were treated with androgen therapy (fluoxymesterone at 1 mg/kg/d: seven patients; danazol at 600 mg/d: 13 patients) for at least 3 months. 11 of them (55%) had an increase in platelet counts by at least 30 x 10(9)/l and a disappearance of bleeding symptoms was seen in 6/6 patients with initial bleeding. A response with neutrophil counts (six cases) or haemoglobin levels (five cases) was less often seen. Treatment was continued for 3+ to 27 months in responders (the dose being reduced by 50% after 6 months). Seven patients on maintenance treatment were still responding. Another patient died while he was still responding, and the remaining three patients relapsed after discontinuation (two cases) and dose reduction to 50% (one case) of the androgen used. Side-effects of treatment were moderate. In our experience, androgen therapy can be useful in patients with 'low risks' MDS (i.e. with marrow blasts < or = 10%) and severe thrombocytopenia, especially because no growth factor regularly active on platelets is currently available.

My notes (saved in your browser only)

MeSH descriptors

Danazol Fluoxymesterone Myelodysplastic Syndromes Thrombocytopenia Adult Aged Aged, 80 and over Danazol Female Fluoxymesterone Hemoglobins Hemoglobins Humans Leukocyte Count Leukocyte Count Male Middle Aged Myelodysplastic Syndromes Neutrophils Neutrophils

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (10)

Cited by (7)

Source provenance

openalex
last seen: 2026-05-11T06:27:45.971503+00:00
pubmed
last seen: 2026-10-08T21:59:14.651011+00:00
unpaywall
last seen: 2026-10-25T06:24:14.523685+00:00
License: CC0 · commercial use OK